Novo Gets US Approval for Wegovy Pill; Copper Hits $12,000 | Bloomberg Brief 12/23/2025

In a landmark development for both pharmaceuticals and industrial markets, Novo Nordisk has secured US approval for an oral version of Wegovy, while simultaneously, copper markets have surged to an unprecedented price milestone above $12,000 per ton.

The copper market's remarkable ascent reflects complex global trade dynamics, with tariff-related movements and ongoing supply constraints driving prices to record heights. This surge comes amid increasing demand from renewable energy sectors and emerging industrial technologies that rely heavily on copper infrastructure.

Investors are closely watching these developments, with market strategists like Mads Pedersen from Human Edge Investment Technology maintaining an optimistic, risk-tolerant stance heading into 2026. The combination of pharmaceutical innovation and industrial commodity strength suggests a potentially transformative period for global markets.

While the Wegovy pill approval represents a significant breakthrough in obesity treatment, the copper price milestone underscores the ongoing structural shifts in global commodity markets. These developments indicate potential opportunities for investors willing to navigate increasingly complex economic landscapes.

As we approach the end of 2025, market participants are advised to monitor these interconnected trends, recognizing that breakthrough technologies and commodity dynamics are increasingly influencing investment strategies across multiple sectors.